Genome-wide Analysis of Disease Progression in Age-Related Macular Degeneration

Qi Yan,Ying Ding,Yi Liu,Tao Sun,Lars G. Fritsche,Traci Clemons,Rinki Ratnapriya,Michael L. Klein,Richard J. Cook,Yu Liu,Ruzong Fan,Lai Wei,Goncalo R. Abecasis,Anand Swaroop,Emily Y. Chew,Daniel E. Weeks,Wei Chen

DOI: https://doi.org/10.1093/hmg/ddy002

2018-01-01

Abstract:Family- and population-based genetic studies have successfully identified multiple disease-susceptibility loci for Age-related macular degeneration (AMD), one of the first batch and most successful examples of genome-wide association study. However, most genetic studies to date have focused on case-control studies of late AMD (choroidal neovascularization or geographic atrophy). The genetic influences on disease progression are largely unexplored. We assembled unique resources to perform a genome-wide bivariate time-to-event analysis to test for association of time-to-late-AMD with similar to 9 million variants on 2721 Caucasians from a large multi-center randomized clinical trial, the Age-Related Eye Disease Study. To our knowledge, this is the first genome-wide association study of disease progression (bivariate survival outcome) in AMD genetic studies, thus providing novel insights to AMD genetics. We used a robust Cox proportional hazards model to appropriately account for between-eye correlation when analyzing the progression time in the two eyes of each participant. We identified four previously reported susceptibility loci showing genome-wide significant association with AMD progression: ARMS2-HTRA1 (P = 8.1 x 10(-43)), CFH (P = 3.5 x 10(-37)), C2-CFB-SKIV2L (P = 8.1 x 10(-10)) and C3 (P = 1.2 x 10(-9)). Furthermore, we detected association of rs58978565 near TNR (P = 2.3 x 10(-8)), rs28368872 near ATF7IP2 (P = 2.9 x 10(-8)) and rs142450006 near MMP9 (P = 0.0006) with progression to choroidal neovascularization but not geographic atrophy. Secondary analysis limited to 34 reported risk variants revealed that LIPC and CTRB2-CTRB1 were also associated with AMD progression (P < 0.0015). Our genome-wide analysis thus expands the genetics in both development and progression of AMD and should assist in early identification of high risk individuals.